DALLAS, Oct. 23 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. announced today that it will make a presentation at the Rodman & Renshaw 8th Annual Healthcare Conference to be held at the New York Palace Hotel in New York City. Rosemary Mazanet, M.D. Ph.D., Acting Chief Executive Officer of Access is scheduled to speak on Monday, November 6, 2006 at 11:40 am EST and will give a corporate overview and discuss the Company’s product opportunities.
Access Pharmaceuticals is an emerging biopharmaceutical company focused on the development of novel therapies for the treatment of cancer and cancer supportive care. The Company’s lead compound, ProLindac(TM), is a novel dach platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. The Company believes that ProLindac’s unique molecular design potentially could eliminate some of the toxic neurological side effects seen in currently marketed Dach platinums. The Company is currently enrolling patients in two Phase II clinical trials, one in ovarian cancer and one in head and neck cancer, and plans to initiate one or more additional Phase II trials, including one in colorectal cancer, within the next six months.
Access’ presentation slides will be available on their website http://www.accesspharma.com after the presentation.
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access’ products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the treatment of patients with mucositis.
The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com .
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties, including the value of our products in the market, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to the risks detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2005 and other reports filed by us with the Securities and Exchange Commission.
Access Pharmaceuticals, Inc.
CONTACT: Stephen B. Thompson, Vice President & CFO of AccessPharmaceuticals, Inc., +1-214-905-5100; or investor relations, Donald C.Weinberger, or media, Alisa Steinberg, both of Wolfe Axelrod WeinbergerLLC, +1-212-370-4500, for Access Pharmaceuticals, Inc.
